
How Microplastics Are Threatening Shark Reproduction
This research fills in a key piece of the puzzle, showing that microplastic pollution isn't just a ... More surface-level problem. It reaches deep into the tissues and reproductive systems of marine life, potentially compromising future generations before they're even born.
Sharks play a critical role in maintaining the balance of ocean ecosystems. Whether they're top predators or mesopredators, their presence helps regulate populations of prey species and support the health of marine food webs. But their survival is under increasing threat. Not only are many shark species slow to grow, reach maturity late and produce few offspring, but they're also facing intense pressure from overfishing and habitat degradation. In fact, the global population of oceanic sharks and rays has dropped by 71% over the past 50 years. While direct human take plays a major role in this decline, another less visible danger is growing: pollution, especially in the form of microplastics.
Microplastics — tiny fragments of plastic less than 5 mm long — are now found across every corner of the ocean. These particles come from the breakdown of larger plastic debris and are made from materials like polyethylene, polypropylene, polyvinylchloride and polystyrene. They've been detected in the guts and tissues of many marine animals such as mammals, seabirds, turtles, zooplankton, fish, and sharks. A recent study focused on spadenose sharks (Scoliodon laticaudus) living along the west coast of India offers new insight into just how deeply these pollutants are infiltrating marine life — and what that might mean for the future of sharks.
Spadenose sharks are small, coastal species that inhabit shallow waters in the Indian and Pacific Oceans. Their size and nearshore habitat make them especially vulnerable to fishing and habitat changes. Led by PhD student Haradhan Ruidas of the Indian Institute of Science Education and Research, Berhampur, a team of researchers examined the gastrointestinal tracts and gonadal tissues of these sharks to measure the presence and concentration of microplastics, assess how these particles could affect reproductive health and identify the types of plastic present. They used the gonadosomatic index (also known as GSI), a tool that compares the weight of reproductive organs to the total body weight, to evaluate reproductive condition. GSI offers a more accurate picture of reproductive investment than raw gonad weight alone since it factors in body size differences.
This study highlights just how widespread and invasive microplastic pollution has become.
The results were alarming.
Microplastics were found in every water sample collected, 97.9% of GI tract samples and 95% of gonadal tissues. The highest concentrations weren't in the stomach or intestines… they were in the gonads. In other words, these pollutants are not just being eaten and passed through the system; they're ending up in reproductive organs. Most of the microplastics detected were fibers (85%), likely originating from synthetic textiles, fishing gear or packaging materials. Flakes and films made up the rest.
What was even more distressing was the fact that female sharks were found to have higher concentrations of microplastics in their gonads compared to males. However, in male sharks, higher levels of microplastics were linked to lower GSI values, suggesting a negative impact on reproductive health. While the exact mechanisms behind this relationship need further investigation, the team says that previous research offers some clues. Studies in other animals have shown that microplastics can migrate through the body, passing into the bloodstream, penetrating cells and even accumulating in the reproductive system. There, they may trigger inflammation, disrupt hormone production and interfere with the development of reproductive cells.
In both lab animals and marine species, microplastics have been linked to reduced testosterone, lower levels of hormones needed for reproduction, and changes in gene expression related to fertility. This new study on spadenose sharks supports the idea that similar effects could be occurring in wild shark populations. Raman spectroscopy — a technique used to identify materials based on their molecular composition — revealed that the microplastics found in the sharks were primarily made of polyethylene and polyamide, both of which are common in packaging and textiles. Sharks, which sit at higher levels in the food chain, may be particularly prone to accumulating these pollutants as they consume contaminated prey over time. For a group of animals already at risk due to slow reproduction, additional reproductive stress caused by pollution could make recovery even harder.
When top predators like sharks begin to suffer, it can signal deeper problems in the ocean. Understanding the physiological impacts of pollution on sharks isn't just important for their survival. It reflects the broader health of marine ecosystems, as the pollution of today is potentially compromising future generations before they're even born.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 days ago
- Yahoo
ScaleReady Announces a G-Rex® Grant has been awarded to Immuneel Therapeutics
ST. PAUL, Minn., June 10, 2025 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation and CellReady, today announced that Immuneel Therapeutics has been awarded a $150,000 G-Rex® Grant to support process development aimed at enhancing the scalability and cost-effectiveness of CAR-T cell manufacturing in India. "The blood cancer burden on India's population is substantial, around 120,000 new cases of lymphoma, leukemia, and multiple myeloma are diagnosed each year. Unfortunately, almost 70,000 Indians will die every year from these afflictions, devastating the lives of their families and communities. To afford access to all Indian patients in need, and to capitalize on the immense commercial potential of our pipeline, we need to think prudently and practically about our manufacturing approach. In the short term, our manufacturing demands are almost 200 drug products per day, and this may increase as CAR-T cell therapies move closer to front line treatment. The only practical way for us to industrialize our production and produce a supply of drug product commensurate with total patient demand is to transition to G-Rex," said Dr. Lakshmikanth Gandikota, Head of R&D, MSAT Intellectual Property, and Translational Research, at Immuneel Therapeutics Limited. "We are extremely impressed by the speed, resourcefulness, creativity, discipline, and entrepreneurialism of the team at Immuneel and are happy to see that India, as a whole, is making significant strides toward CAR-T availability. It gives us a great sense of satisfaction to be in a position to help bring hope to cancer patients in India, one G-Rex at a time," said John Wilson, CEO of Wilson Wolf and co-inventor of G-Rex. As part of Immuneel's G-Rex Grant, they will perform process development, qualification, and validation of a G-Rex based CAR-T cell therapy production approach to dramatically increase the throughput capacity of their state-of-the-art, 12,000 square foot GMP facility. Located in Bengaluru and opened in 2021, Immuneel's Integrated Cell Therapy Development and Manufacturing Facility was the first of its kind in India and is designed to bring breakthrough cell and gene therapies to millions of patients in India. Lastly, Immuneel's G-Rex Grant will support the requisite comparability studies necessary to support a post-CAR-T approval manufacturing change from their difficult to scale low throughput all-in-one manufacturing equipment to a much simpler high throughput G-Rex centric approach. The high popularity of ScaleReady's G-Rex Grant Program led ScaleReady to increase award funds from the original amount of $20M to a total of $30M directed towards saving recipients significant time and money by expediting the path to optimized cell and gene-modified cell therapy manufacturing. Two hundred grants have already been awarded with over 50 new applications in the queue. Each G-Rex Grant recipient can obtain up to $300,000 and gain access to exclusive support from ScaleReady's growing consortium of G-Rex Grant Partners who bring best-in-class tools and technologies as well as unparalleled knowledge and expertise in the areas of cGMP manufacturing, quality and regulatory affairs, CGT business operations, and more. For more information about the G-Rex® Grant Program, please contact info@ About ScaleReadyScaleReady provides the field of cell and gene-modified cell therapy (CGT) with a G-Rex centric manufacturing platform that enables the world's most practical, flexible, scalable, and affordable CGT drug product development and manufacturing. The G-Rex manufacturing platform is currently used by a rapidly growing list of over 800 organizations and is producing drug products for approximately 50% of CGT clinical trials as well as 5 commercially approved CGT drugs. CGT entities relying on the breadth and scope of ScaleReady's expertise can expect to save years of time and millions of dollars on the path to CGT commercialization. For more information about the ScaleReady G-Rex® Grant Program, please contact info@ About Wilson Wolf ManufacturingWilson Wolf ( is dedicated to simplifying cell and gene-modified cell (CGT) therapy research, process development, and manufacturing. This is being accomplished through its scalable G-Rex technology, which is used throughout the world in CGT applications ranging from basic research to commercial drug production. Wilson Wolf's mission is to create hope for cancer patients, one G-Rex® device at a time. About Bio-Techne CorporationBio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne, in partnership with Wilson Wolf, is creating products such as media and cytokines that are specifically tailored to G-Rex® Bioreactors, including right-sized reagent quantities in containers that are tailored to high throughput closed-system manufacturing. For more information on Bio-Techne and its brands, please visit or follow the Company on social media at: Facebook, LinkedIn, Twitter or YouTube. Contact: David Clair, Vice President, Investor Relations & Corporate About CellReady LLCCellReady is the world's first and only G-Rex centric contract development and manufacturing organization (CDMO) specializing in G-Rex based cell and gene-modified cell therapy development and manufacturing. The company offers a wide range of services to support the development and commercialization of these therapies. CellReady's mission is to create hope for cancer patients, one G-Rex® process at a time. About Immuneel therapeutics Private LimitedImmuneel Therapeutics Private Limited is a cutting-edge biotechnology company based in Bangalore, India, at the forefront of advancing cell and gene therapies, as well as personalized immunotherapies, for cancer patients in India. As a research-driven and fully integrated organization, Immuneel is dedicated to making next-generation cancer treatments accessible and affordable, with a strong focus on innovation and clinical impact. The company's mission is to democratize advanced therapies by developing and commercializing breakthrough solutions tailored to the needs of Indian patients. As part of its growing portfolio, Immuneel has licensed and commercialized Qartemi® (varnimcabtagene autoleucel), a CD19 CAR-T cell therapy approved by India's Central Drugs Standard Control Organization (CDSCO) for the treatment of adult B-cell non-Hodgkin lymphoma a novel therapy for blood cancer, further demonstrating its commitment to transforming cancer care in India. Immuneel has a robust pipeline of CAR-T therapies for various indications in Oncology and AutoImmune diseases For more information, please visit: View original content to download multimedia: SOURCE Bio-Techne Corporation
Yahoo
3 days ago
- Yahoo
India to send first astronaut on mission to International Space Station
The first Indian astronaut to visit the International Space Station is due to blast off as part of an effort by the world's most populous nation to catch up with the US, Russia and China in human space flight missions. Shubhanshu Shukla, a 39-year-old air force fighter pilot, is is part of four-person mission launching on Tuesday from the US with the private company Axiom Space, which is using a SpaceX capsule. He will be the third astronaut of Indian origin to reach orbit, following Rakesh Sharma, who was part of a 1984 flight onboard a Soviet Soyuz spacecraft, and Kalpana Chawla, who was born in India but became a US citizen and flew on two space shuttle missions, including the 2003 Columbia flight that ended in disaster when the spacecraft disintegrated, killing all seven astronauts onboard. 'I truly believe that even though, as an individual, I am travelling to space, this is the journey of 1.4 billion people,' Shukla was quoted as saying by the Hindu newspaper this year. Shukla said he hoped to 'ignite the curiosity of an entire generation in my country'. India's department of space has called the trip a 'defining chapter' in its ambitious space exploration programme. The International Space Station mission (ISS) 'stands as a symbol of a confident, forward-looking nation ready to reclaim its place in the global space race', the agency said before the launch. 'His journey is more than just a flight – it's a signal that India is stepping boldly into a new era of space exploration.' New Delhi has paid more than $60m for the mission, according to Indian media reports. The prime minister, Narendra Modi, has announced plans to send a person to the moon by 2040. The Indian Space Research Organisation, meanwhile, is planning to launch its own human spaceflight mission, called Gaganyaan, or 'sky craft' in Hindi, in 2027. Shukla is a contender to be part of that trip. Shukla trained at the Yuri Gagarin Cosmonaut Training Center in Russia in 2020, before undertaking further training at the ISRO's centre in Bengaluru. He has said the journey aboard the Axiom Mission 4, and the expected 14 days on the ISS, will provide 'invaluable' lessons to bring back home. Shukla will be led by the mission commander, Peggy Whitson, a former Nasa astronaut and an Axiom employee, and joined by the European Space Agency astronaut Sławosz Uznański-Wiśniewski, of Poland, and Tibor Kapu, of Hungary. Related: How space exploration can improve life on Earth | Leigh Phillips They will conduct 60 scientific studies, including microgravity research, earth observation, and life, biological and material sciences experiments. India's space programme has grown considerably in size and momentum in the last decade, matching the achievements of established powers at a much cheaper price. In August 2023, it became the fourth nation to land an unmanned craft on the moon after Russia, the US and China. Agence France-Presse contributed to this report


Business Upturn
5 days ago
- Business Upturn
Mukesh Ambani donates Rs 151 crore to alma mater ICT in honour of Professor MM Sharma
By Aditya Bhagchandani Published on June 7, 2025, 12:32 IST Mukesh Ambani, Chairman and Managing Director of Reliance Industries, has announced an unconditional grant of Rs 151 crore to the Institute of Chemical Technology (ICT), Mumbai—his alma mater—during a special event commemorating the biography launch of Professor MM Sharma titled 'Divine Scientist' . Ambani, who studied at the institute in the 1970s when it was known as UDCT (University Department of Chemical Technology), spent over three hours at the campus, reflecting on the impact of his very first lecture by Prof. Sharma. He described Prof. Sharma as a key figure who quietly shaped India's economic reforms by advocating for the dismantling of the license-permit raj to promote scale and global competitiveness in Indian industry. Comparing Prof. Sharma to his father, Dhirubhai Ambani, Mukesh said both visionaries believed in the transformative power of science, technology, and private entrepreneurship. 'These two bold visionaries believed that science and technology, in alliance with private entrepreneurship, would open the floodgates of prosperity,' he stated. Referring to Prof. Sharma as a Rashtra Guru or 'Guru of Bharat,' Ambani made the donation as a form of 'Guru Dakshina', acting on the professor's personal request. 'He told me, 'Mukesh you have to do something big for ICT,' and I am very pleased to announce that,' Ambani said. Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.